Advances in percutaneous lung tumor therapy: 2019 update

Hiroshi Kodama, Koichiro Yamakado, Junichi Taniguchi, Atsushi Ogasawara, Yasukazu Kako, Haruyuki Takaki, Kaoru Kobayashi


Malignant lung tumors are a leading cause of death worldwide (1). Surgical resection is the gold standard treatment, but surgical candidates are fewer than 30% of all patients because of poor respiratory function, advanced age, and multiple comorbidities (2). For these patients, alternative treatments include systemic therapy including cytotoxic chemotherapy, molecular target therapy and immune check inhibitors, radiation therapy, and percutaneous thermal ablation therapy such as radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation. We herein describe the latest evidence and future prospects for percutaneous ablation therapy of lung cancer.